Get the Stockscreener App
20.68
1.05%
-0.22
Apollomics Inc stock is traded at $20.68, with a volume of 40,527.
It is down -1.05% in the last 24 hours and up +37.41% over the past month.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
See More
Previous Close:
$20.90
Open:
$20.69
24h Volume:
40,527
Relative Volume:
0.58
Market Cap:
$44.32M
Revenue:
-
Net Income/Loss:
$-53.86M
P/E Ratio:
-0.3797
EPS:
-54.4704
Net Cash Flow:
$-28.76M
1W Performance:
+20.02%
1M Performance:
+37.41%
6M Performance:
+217.67%
1Y Performance:
+104.15%
1-Day Range:
$20.68
$23.00
1-Week Range:
$17.00
$24.15
52-Week Range:
$3.659
$42.12
Apollomics Inc Stock (APLM) Company Profile
Compare APLM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
20.68 | 44.80M | 0 | -53.86M | -28.76M | -54.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apollomics Inc Stock (APLM) Latest News
Aug Outlook: Can Apollomics Inc Equity Warrant stock deliver 10 annual returns2025 Risk Factors & Low Volatility Stock Suggestions - moha.gov.vn
Precision Trading with Apollomics Inc. (APLM) Risk Zones - Stock Traders Daily
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 - marketscreener.com
Apollomics Reports First Half 2025 Financial Results - GlobeNewswire
Will Apollomics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Accurate Entry/Exit Alerts - Улправда
Will Apollomics Inc. Equity Warrant stock gain from lower inflationGDP Growth & Free Fast Entry Momentum Trade Alerts - Улправда
Why Apollomics Inc. stock could be next big winnerJuly 2025 PostEarnings & AI Enhanced Market Trend Forecasts - Улправда
How Apollomics Inc. stock benefits from tech adoption2025 Major Catalysts & Safe Capital Allocation Plans - Улправда
Is Apollomics Inc. Equity Warrant stock ready for breakoutJuly 2025 Review & High Accuracy Trade Alerts - DonanımHaber
Will Apollomics Inc. stock maintain momentum in 2025Wall Street Watch & Momentum Based Trading Signals - DonanımHaber
How Apollomics Inc. Equity Warrant stock reacts to Fed rate cutsEarnings Beat & Scalable Portfolio Growth Ideas - Улправда
Why Apollomics Inc. stock is favored by pension funds2025 Momentum Check & Community Trade Idea Sharing Platform - Улправда
How Apollomics Inc. (APLM) Affects Rotational Strategy Timing - Stock Traders Daily
Apollomics (APLM) terminates APL-122 collaboration and license with Edison - Stock Titan
Total debt per share of Apollomics Inc. Warrant 2023-01.04.28 on Apollomics – NASDAQ:APLMW - TradingView — Track All Markets
Market Wrap: Will Apollomics Inc stock deliver shareholder valueWeekly Profit Recap & Expert Curated Trade Setups - BỘ NỘI VỤ
Book value per share of Apollomics Inc. Warrant 2023-01.04.28 on Apollomics – NASDAQ:APLMW - TradingView
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
How Apollomics Inc. Equity Warrant stock compares to industry benchmarksJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
(APLM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
APLM Stock Institutional Owners - Quiver Quantitative
Will Apollomics Inc. stock outperform tech sector in 2025Weekly Investment Recap & Smart Money Movement Tracker - Newser
How Apollomics Inc. Equity Warrant stock reacts to global recession fearsJuly 2025 Market Mood & High Yield Stock Recommendations - Newser
Apollomics (APLM) Stock Analysis Report | Financials & Insights - Benzinga
Can Apollomics Inc. stock deliver surprise earnings beatPortfolio Gains Report & Risk Controlled Stock Alerts - BỘ NỘI VỤ
Apollomics Inc trading halted, volatility trading pause - MSN
Apollomics announces settlement of Cayman litigation - MSN
Will Apollomics Inc. Equity Warrant stock continue upward momentumPortfolio Performance Report & Accurate Technical Buy Alerts - newser.com
Leading vs lagging indicators on Apollomics Inc. Equity Warrant performanceQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Will Apollomics Inc. Equity Warrant stock beat EPS estimatesJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
How supply chain issues affect Apollomics Inc. Equity Warrant stockPortfolio Risk Summary & Real-Time Market Sentiment Reports - newser.com
Apollomics Announces Settlement of Cayman Litigation - GlobeNewswire
Apollomics (Nasdaq: APLM) reaches Cayman settlement with $5M plus legal fees - Stock Titan
Apollomics entered settlement agreement related to legal proceedings by two minority investors of co - MarketScreener
[6-K] Apollomics Inc. Current Report (Foreign Issuer) | APLM SEC FilingForm 6-K - Stock Titan
Can Apollomics Inc. Equity Warrant stock resist sector downturnsEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Apollomics Inc. Equity Warrant’s volatility index tracking explainedJuly 2025 Earnings & Daily Stock Trend Reports - newser.com
How strong is Apollomics Inc. Equity Warrant stock revenue growth2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Is Apollomics Inc. Equity Warrant a candidate for recovery play2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What to do if you’re stuck in Apollomics Inc.Weekly Trend Summary & Technical Entry and Exit Alerts - newser.com
Apollomics Inc. Equity Warrant stock trendline breakdownPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - newser.com
Full technical analysis of Apollomics Inc. Equity Warrant stockMarket Sentiment Review & Real-Time Volume Trigger Notifications - newser.com
Published on: 2025-11-19 04:55:09 - newser.com
How Apollomics Inc. Equity Warrant stock reacts to bond yieldsTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):